CR20170546A - Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios - Google Patents

Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios

Info

Publication number
CR20170546A
CR20170546A CR20170546A CR20170546A CR20170546A CR 20170546 A CR20170546 A CR 20170546A CR 20170546 A CR20170546 A CR 20170546A CR 20170546 A CR20170546 A CR 20170546A CR 20170546 A CR20170546 A CR 20170546A
Authority
CR
Costa Rica
Prior art keywords
triazine
antiparasitary
agents
imidazo derivatives
compound
Prior art date
Application number
CR20170546A
Other languages
English (en)
Inventor
Timothy James Miles
Eun Jung; Ko
Elisabet Viayna Gaza
Michael George; Thomas
Martin Maria Marco
Lars Henrik Sandberg
Stephen Brand
Ian; Gilbert
Original Assignee
The Univ Of Dundee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Dundee, Glaxosmithkline Ip Dev Ltd filed Critical The Univ Of Dundee
Publication of CR20170546A publication Critical patent/CR20170546A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de Formula (I), o una de sus sales, composiciones que comprenden el compuesto, procedimientos para su preparación y su uso en terapia, por ejemplo, en el tratamiento de enfermedades parasitarias tales como enfermedad de Chagas, tripanosomiasis africana humana (HAT) y leishmaniasis, particularmente leishmaniasis visceral (VL)
CR20170546A 2015-05-29 2016-05-26 Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios CR20170546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382283 2015-05-29
PCT/EP2016/061887 WO2016193111A1 (en) 2015-05-29 2016-05-26 Imidazo[1,2-b][1,2,4]triazine derivatives as antiparasitic agents

Publications (1)

Publication Number Publication Date
CR20170546A true CR20170546A (es) 2018-04-02

Family

ID=53398015

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170546A CR20170546A (es) 2015-05-29 2016-05-26 Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios

Country Status (14)

Country Link
US (1) US10065965B2 (es)
EP (1) EP3303336A1 (es)
JP (1) JP2018516265A (es)
CN (1) CN107922419A (es)
AR (1) AR104749A1 (es)
AU (1) AU2016269626B2 (es)
BR (1) BR112017025668A2 (es)
CA (1) CA2987329A1 (es)
CL (1) CL2017003025A1 (es)
CO (1) CO2017011969A2 (es)
CR (1) CR20170546A (es)
TW (1) TW201713661A (es)
UY (1) UY36688A (es)
WO (1) WO2016193111A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127627A1 (en) 2016-01-21 2017-07-27 The University Of North Carolina At Chapel Hill Compounds for treatment of trypanosomes and neurological pathogens and uses thereof
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EA039324B1 (ru) * 2017-11-06 2022-01-13 Новартис Аг 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
CN108129409B (zh) * 2018-01-22 2020-07-03 三金集团湖南三金制药有限责任公司 一种改进的合成拉莫三嗪的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151799A2 (en) * 2009-06-26 2010-12-29 University Of Massachusetts Compounds for modulating rna binding proteins and uses therefor
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
PE20160865A1 (es) * 2013-12-19 2016-09-03 Novartis Ag Derivados de [1,2,4] triazolo [1,5-a]pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias tales como leishmaniasis

Also Published As

Publication number Publication date
AU2016269626A1 (en) 2017-12-14
US10065965B2 (en) 2018-09-04
WO2016193111A1 (en) 2016-12-08
CL2017003025A1 (es) 2018-03-16
JP2018516265A (ja) 2018-06-21
CN107922419A (zh) 2018-04-17
CA2987329A1 (en) 2016-12-08
CO2017011969A2 (es) 2018-02-09
AU2016269626B2 (en) 2019-05-30
UY36688A (es) 2016-12-30
US20180141949A1 (en) 2018-05-24
TW201713661A (zh) 2017-04-16
EP3303336A1 (en) 2018-04-11
BR112017025668A2 (pt) 2018-08-07
AR104749A1 (es) 2017-08-09

Similar Documents

Publication Publication Date Title
ECSP20040257A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CO2018004933A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
NI201800033A (es) Derivados de 8-[6-[3-(amino)propoxi]-3piridil]-1-isopropil-imidazo[4, 5-c]quinolin -2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer.
UY36285A (es) Compuestos que inhiben la proteína mcl-1
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CO2017011969A2 (es) Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios
ECSP16067921A (es) Derivados de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias tales como leishmaniasis
UY38625A (es) Compuestos y su uso en el tratamiento del cáncer
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
NI201900094A (es) COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
CY1124151T1 (el) Ενωσεις
CL2015001381A1 (es) Método para preparar derivados de feniloximetil-nitro-imidazol; y su uso para el tratamiento de enfermedades parasitarias y en particular la enfermedad de chagas y la tripanosomiasis humana africana